The price of Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $82.30 in the last session, up 4.26% from day before closing price of $78.94. In other words, the price has increased by $+3.36 from its previous closing price. On the day, 592932 shares were traded. AXSM stock price reached its highest trading level at $82.30 during the session, while it also had its lowest trading level at $78.52.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at AXSM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.52 and its Current Ratio is at 3.63. In the meantime, Its Debt-to-Equity ratio is 0.98 whereas as Long-Term Debt/Eq ratio is at 0.97.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on February 06, 2024, initiated with a Buy rating and assigned the stock a target price of $111.
On January 25, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $126.
On December 13, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $125.Citigroup initiated its Buy rating on December 13, 2023, with a $125 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 15 when Coleman Mark sold 18,572 shares for $75.18 per share. The transaction valued at 1,396,189 led to the insider holds 403,856 shares of the business.
Coleman Mark sold 11,016 shares of AXSM for $828,241 on Sep 15. The Director now owns 25,097 shares after completing the transaction at $75.19 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 3.74B and an Enterprise Value of 3.54B. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.40 while its Price-to-Book (P/B) ratio in mrq is 20.41. Its current Enterprise Value per Revenue stands at 13.08 whereas that against EBITDA is -15.73.
Stock Price History:
Over the past 52 weeks, AXSM has reached a high of $98.40, while it has fallen to a 52-week low of $53.71. The 50-Day Moving Average of the stock is 85.11, while the 200-Day Moving Average is calculated to be 75.28.
Shares Statistics:
According to the various share statistics, AXSM traded on average about 697.43K shares per day over the past 3-months and 949.83k shares per day over the past 10 days. A total of 47.35M shares are outstanding, with a floating share count of 38.75M. Insiders hold about 18.16% of the company’s shares, while institutions hold 80.96% stake in the company. Shares short for AXSM as of Jan 31, 2024 were 7.49M with a Short Ratio of 10.74, compared to 8.42M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 15.83% and a Short% of Float of 19.07%.
Earnings Estimates
The company has 11 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$1.19 for the current quarter, with a high estimate of -$0.99 and a low estimate of -$1.39, while EPS last year was -$0.26. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.7 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$1.85 and -$4.91 for the fiscal current year, implying an average EPS of -$3.71. EPS for the following year is $0.68, with 11 analysts recommending between $4.9 and -$2.6.
Revenue Estimates
According to 11 analysts, the current quarter’s revenue is expected to be $74.45M. It ranges from a high estimate of $79.85M to a low estimate of $65.7M. As of the current estimate, Axsome Therapeutics Inc’s year-ago sales were $26.07M, an estimated increase of 185.60% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $88.09M, an increase of 115.20% less than the figure of $185.60% in the same quarter last year. There is a high estimate of $97.5M for the next quarter, whereas the lowest estimate is $80.6M.
A total of 15 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $450.08M, while the lowest revenue estimate was $339.58M, resulting in an average revenue estimate of $380.53M. In the same quarter a year ago, actual revenue was $270.6M, up 40.60% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $687.88M in the next fiscal year. The high estimate is $942.55M and the low estimate is $515.7M. The average revenue growth estimate for next year is up 80.80% from the average revenue estimate for this year.
